ThromboGenics’ JETREA® Gains First Asian Approval in Malaysia
News Apr 22, 2014
ThromboGenics NV has announced that JETREA® (ocriplasmin) has been approved in Malaysia for the treatment of adults with vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns. The approval, the first in Asia, was gained following a Priority Review that was granted in September 2013.
ThromboGenics’ licensing partner Alcon, the global leader in eye health, holds the commercialization rights to JETREA® outside the US and will be responsible for the launch of the drug in Malaysia, the first market in Asia.
Alcon, the second largest division of Novartis, acquired the rights to commercialize JETREA® outside the United States in March 2012.
Alcon has already launched JETREA® in Europe; this novel pharmacological treatment is available and reimbursed in the UK, Germany, Denmark, Finland, Norway, Sweden, Ireland and The Netherlands. JETREA® is also available and reimbursed in Canada. In Europe, patients in Belgium, France, Spain and Italy have also been treated with JETREA®.
ThromboGenics is commercializing the drug in the US where it is approved for the treatment of patients with symptomatic vitreomacular adhesion (VMA).
Dr Patrik De Haes, CEO of ThromboGenics, says: “The approval of JETREA® in Malaysia, the first in Asia, is a further important milestone in ensuring the global availability of this novel medicine. We are optimistic that, in time, JETREA® will become the treatment of choice for the earlier treatment of patients with VMT in Asia.”
Ingestible Drug-Delivery Materials May Improve Patient Treatment ComplianceNews
Hydrogel-based capsules could expand and reside in the GI tract for days, slowly releasing medication.READ MORE
Researchers Develop New Method to Generate Human AntibodiesNews
Researchers hope their approach will help researchers rapidly generate therapeutic antibodies for the treatment of infectious diseases and other conditions such as cancer.READ MORE
Large-Scale Production of Living Brain Cells Enables Entirely New ResearchNews
After performing a biopsy on the patient, the skin cells are transformed into brain cells that effectively imitate the disease and the age of the patient.READ MORE
Comments | 0 ADD COMMENT
8th International Symposium on Recent Advances in Food Analysis (RAFA 2017)
Nov 07 - Nov 10, 2017
6th Edition of International Conference on Pharmacognosy and Medicinal Plants
Apr 16 - Apr 17, 2018
International Conference and Exhibition on Nanomedicine and Nanotechnology
Nov 23 - Nov 24, 2017